In an unusual move, the Canadian company Biovail is suing a shortseller for more than $250 million, claiming he used false and malicious rumors to depress the firm's share price, according to local reports.
"As this litigation goes through the judicial system, the kinds of tactics that are being used by shortsellers, specifically in the US markets, will stun the investment community," commented Biovail's chairman Eugene Melnyk in an interview with Canada's Financial Post.
The firm's share price has fallen over 35% since May 22 to C$34.50 ($25.12) on the Toronto Stock Exchange. The shares are valued at around $25 on the New York, Stock Exchange.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze